Verapamil SR in Adults With Type 1 Diabetes (Ver-A-T1D)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04545151 |
|
Recruitment Status :
Recruiting
First Posted : September 10, 2020
Last Update Posted : July 5, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This study has been set up within the framework of the INNODIA network. INNODIA is a global partnership between 31 academic institutions, 6 industrial partners, a small sized enterprise and 2 patient organizations, bringing their knowledge and experience together with one common goal: "To fight type 1 diabetes". (www.innodia.eu) The overall aim of INNODIA is to advance in a decisive way how to predict, stage, evaluate and prevent the onset and progression of type 1 diabetes (T1D).
For this, INNODIA has established a comprehensive and interdisciplinary network of clinical and basic scientists, who are leading experts in the field of T1D research in Europe and UK (United Kingdom), with complementary expertise from the areas of immunology, Beta-cell biology, biomarker research and T1D therapy, joining forces in a coordinated fashion with industry partners and two foundations, as well as with all major stakeholders in the process, including regulatory bodies and patients with T1D and their families.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Diabetes Mellitus, Type 1 | Drug: Verapamil SR 120 mg Drug: Placebo | Phase 2 |
The study is a multicenter, randomized, double-blind, placebo-controlled study in volunteers with newly diagnosed diabetes mellitus type 1 (within 6 weeks after diagnosis).
The purpose of the clinical trial is to confirm the effect of 360mg Verapamil sustained release (SR) administered orally once daily (titrated over the first 3 months from 120 mg to 360 mg) on the preservation of beta-cell function measured as stimulated C-peptide after 12 months compared to placebo.
The study has a cross-over design and a duration of approximately 24 months, consisting of 3 telephone visits and 7 visits at the trial site. The duration of the treatment phase with verapamil is 12 months, and an additional (optional) follow-up visit will be carried out 12 months after completion of the study. The study procedures are identical in all 20 clinical centres across Europe and the UK.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 138 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Masking Description: | Trial participants and research teams will be blinded to the treatment group for the duration of the trial. The double blinding will be achieved by providing verapamil SR identical placebo tablets. |
| Primary Purpose: | Treatment |
| Official Title: | A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D) |
| Actual Study Start Date : | February 8, 2021 |
| Estimated Primary Completion Date : | February 2024 |
| Estimated Study Completion Date : | February 2024 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Verapamil SR
Eligible participants will be randomised into the Verapamil SR arm and receive instructions on frequency of administration (daily intake). 80 participants on the experimental arm are expected to complete the trial.
|
Drug: Verapamil SR 120 mg
For use as a test product in this blinded study, the IMP will be modified by re-packaging. The film-coated tablets will be squeezed from their blisters and filled into HDPE Twist-Off bottles. Each bottle will be labeled as required per country requirement. Labels will be blinded. Drug administration:
Other Names:
|
|
Placebo Comparator: Placebo
Eligible participants will be randomised into the placebo arm and receive instructions on frequency of administration (daily intake). 40 participants on the control arm are expected to complete the trial. |
Drug: Placebo
The matching placebo will be filled into HDPE Twist-Off bottles, in the same way as the verum. Each bottle will be labeled as required per country requirement. Labels will be blinded. Drug administration:
Other Name: Matching Placebo for Verapamil SR 120 mg |
- Area under the stimulated C-peptide response curve [ Time Frame: At 12 months ]The primary objective is to determine the changes in stimulated C-peptide response during the first two hours of a mixed meal tolerance test (MMTT) at baseline and after 12 months for 360mg Verapamil SR administered orally once daily versus placebo.
- Area under the stimulated C-peptide response curve [ Time Frame: At 3, 6, 9 and 24 months ]The area under the stimulated C-peptide response curve over the first two hours of a mixed meal tolerance test (MMTT)
- Proinsulin, Insulin, Pro-IAPP and Proglucagon secretion [ Time Frame: At baseline and 3, 6, 9 and 12 months ]Proinsulin, Insulin, Pro-IAPP and Proglucagon during the first two hours of a mixed meal tolerance test (MMTT)
- Fasting C-peptide [ Time Frame: At 12 months ]To determine the effects of 360mg Verapamil SR administered orally once daily on fasting C-peptide and Dried Blood Spot (DBS) C-peptide measurements over time.
- DBS C-peptide [ Time Frame: At baseline, week 4, week 8, and 3, 6, and 9 months ]The DBS (Dried blood spot) C-peptide measurements at all observation times
- Change in HbA1c [ Time Frame: Baseline, 12 and 24 months ]To determine the effects of 360mg Verapamil SR administered orally once daily on HbA1c daily total insulin dose and continous glucose monitoring (CGM) time in range.
- Severe hypoglycaemic episodes [ Time Frame: Baseline to 12 months ]Number of treatment emergent severe hypoglycaemic episodes. Severe hypoglycaemia denotes severe cognitive impairment requiring external assistance for recovery according to the American Diabetes Association (ADA)
- DKA [ Time Frame: Baseline to 12 months ]Number of treatment emergent episodes of diabetic ketoacidosis
- Change in insulin requirements [ Time Frame: Baseline, 12 and 24 months ]Change in insulin requirements, baseline to 12 months as the daily total dose (three days average) in units per kg body weight (BW)
- Change in T1D associated autoantibodies [ Time Frame: Baseline to 12 months ]Change in T1D associated autoantibodies (GADA, IAA, IA-2A and ZnT8A) from baseline to 12 months
- Continous glucose monitoring (CGM) [ Time Frame: At Baseline and every 2 weeks prior to each visit (week 4, week 8, and 3, 6, and 9 months) ]Continous glucose monitoring (CGM) time in range (70-140 mg/dL, 3.9-7.8 mmol/L) and (70-180 mg/dL, 3.9-10.0 mmol/L), time above range (>180 mg/dL, >10.0 mmol/L), time below range (<70 mg/dL, < 3.9 mmol/L)
- Quality of life: DTSQs questionnaire [ Time Frame: At week 4 , month 6 and month 12. ]
Patients' quality of life will be assessed by participant-reported outcome measures (PROMS):
the Diabetes Treatment Satisfaction Questionnaire - DTSQs
- Quality of life: DTSQc questionnaire [ Time Frame: At month 12 ]
Patients' quality of life will be assessed by participant-reported outcome measures (PROMS):
the Diabetes Treatment Satisfaction Questionnaire - DTSQc
- Quality of life: ADDQoL questionnaire [ Time Frame: At month 6 and at month 12 ]
Patients' quality of life will be assessed by participant-reported outcome measures (PROMS):
· the Audit of Diabetes Dependent Quality of Life - ADDQoL
- Quality of life: HypoFear questionnaire [ Time Frame: At week 4 , at month 6 and at month 12 ]Patients' quality of life will be assessed by participant-reported outcome measures (PROMS): the Hypoglycaemia Fear Survey - HFS
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Have given written informed consent
- Age ≥18 and <45 years at consent
- Must have a diagnosis of T1D of within 6 weeks duration at screening (from date of the first insulin injection)
- Must have at least one or more diabetes-related autoantibodies present at screening: GADA, IA-2A and/or ZnT8A
- Must have fasting C-peptide levels ≥100 pmol/L measured at screening
- Be willing to comply with intensive diabetes management
Exclusion Criteria:
- Be immunodeficient or have clinically significant chronic lymphopenia: Leukopenia (< 3,000 leukocytes /µL), neutropenia (<1,500 neutrophils/µL), lymphopenia (<800 lymphocytes/µL), or thrombocytopenia (<100,000 platelets/µL)
- Have active signs or symptoms of acute infection at the time of screening
- Be currently pregnant or lactating, or anticipate getting pregnant during the 12 months study period
- Require use of immunosuppressive agents including chronic use of systemic steroids
- Have evidence of current or past human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C infection
- Have any complicating medical issues or abnormal clinical laboratory results that may interfere with study conduct, or cause increased risk to include pre-existing cardiac disease, chronic obstructive pulmonary disease (COPD), sickle cell disease, neurological, or blood count abnormalities as judged by the investigator
- Have a history of malignancies other than skin
- History of liver insufficiency or laboratory evidence of liver dysfunction with aspartate aminotransferase (AST) or alanine transaminase (ALT) greater than 3 times the upper limits of normal
- History of renal insufficiency or evidence of renal dysfunction with creatinine greater than 1.5 times the upper limit of normal
- Current or ongoing use of non-insulin pharmaceuticals that affect glycaemic control within prior 7 days of screening
- Use of any other investigational drug in the previous 30 days and/or intent on using any investigational drug for the duration of the trial
- Current use of Verapamil or other calcium channel blockers
- Known hypersensitivity to Verapamil or to any of its excipients
- Concomitant medication known for significantly inducing or inhibiting CYP3A4 and/or glycoprotein-P metabolism
- Intake of grapefruit juice, licorice, St.John's Wort, cannabidiol, ginkgo biloba
- Substrate intake of CYP3A4 and/or glycoprotein-P metabolism, as judged by the investigator
- Hypotension (of less than 100mmHg systolic), sick sinus syndrome (except patients with a functioning artificial pacemaker), uncompensated heart failure or severe left ventricular dysfunction; marked bradycardia (less than 50 beats/minute), atrial flutter or atrial fibrillation in the presence of an accessory bypass tract (e.g. Wolff-Parkinson-White syndrome), hypertrophic cardiomyopathy, acute myocardial infarction, attenuated neuromuscular transmission (e.g. by myasthenia gravis, Lambert-Eaton syndrome, advanced Duchenne muscular dystrophy)
- ECG second or third degree atrioventricular block; Incomplete branch block
- Any condition that in the investigator's opinion may adversely affect study participation or may compromise the study results
- Current use of ß-blockers
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04545151
| Contact: Martina Brunner, MSc | +43 316 385 ext 72841 | martina.brunner@medunigraz.at | |
| Contact: Karin Brandner, MSc | +43 316 385 ext 72800 | karin.brandner@medunigraz.at |
Show 23 study locations
| Principal Investigator: | Thomas R. Pieber, MD, Prof | Medical University of Graz | |
| Principal Investigator: | Dayan Colin, MD, Prof | Cardiff University |
| Responsible Party: | Medical University of Graz |
| ClinicalTrials.gov Identifier: | NCT04545151 |
| Other Study ID Numbers: |
Ver-A-T1D 2020-000435-45 ( EudraCT Number ) |
| First Posted: | September 10, 2020 Key Record Dates |
| Last Update Posted: | July 5, 2022 |
| Last Verified: | June 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
INNODIA Typ-1 Diabetes Verapamil Beta cell C-peptide |
|
Diabetes Mellitus Diabetes Mellitus, Type 1 Verapamil Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Autoimmune Diseases Immune System Diseases |
Anti-Arrhythmia Agents Calcium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Calcium-Regulating Hormones and Agents Physiological Effects of Drugs Vasodilator Agents |